Research design and methods
We used the same source population and methods that we have previously employed to compare these two strategies in patients with diabetes and cardiovascular disease [6] . In this paper, for the first time, we present results for patients with diabetes regardless of cardiovascular disease. Only one other clinical trial, the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT), [7] examined epoetin use among chronic kidney disease patients with diabetes but our study differs and is novel in two important ways: 1) TREAT enrolled predialysis patients while our study includes end-stage renal disease (ESRD) patients; and 2) TREAT evaluated a near normal hematocrit value (>39%) versus placebo while our study compared the Food and Drug Administration (FDA)-recommended strategy of hematocrit <33% with the commonly used strategy of hematocrit 34-39%.
We emulate a randomized trial by using observational data from the United States Renal Data System (USRDS), which includes the universe of US dialysis patients. We identified incident hemodialysis patients with diabetes who were 65 years and older and received their first ESRD service in 2006-2008. The inclusion criteria were age 65 years or older and evidence of diabetes after 3 months on dialysis. The exclusion criteria were: history of cancer prior to ESRD (studies suggest that patients with cancer might respond differently to epoetin therapy [8, 9] , no epoetin therapy in the first 30 days of outpatient dialysis, kidney transplantation or use of peritoneal dialysis modality or darbepoetin (a derivative form of epoetin used primarily in inpatient settings) before baseline, hematocrit <24% at baseline, incomplete baseline covariate values, baseline data inconsistent with the strategies of interest, patients who did not reach hematocrit of 30% at baseline (non responders), or follow-up started in a nondialysis facility (Supplemental Figure  1) . A patient was classified as 'diabetic' if diabetes was reported
Introduction
Morbidity and mortality rates for persons with diabetes and chronic kidney disease (CKD) in the US are high [1, 2] . One potential area for improvement of patient survival is the management of anemia, the most common complication among dialysis patients. Yet, twenty years after the introduction of erythropoiesisstimulating agents (ESA; including epoetin, epoetin alfa, and darbepoetin) to treat anemia, there is still considerable uncertainty in the nephrology community regarding an optimal hematocrit target among dialysis patients with diabetes as a comorbid condition [3] [4] [5] . We conducted an observational analysis of elderly dialysis patients with diabetes to compare their mortality and cardiovascular risk under two clinical strategies of to be the primary cause of renal failure and/or diabetes was listed as a co-morbid condition on the Medical Evidence Form 2728 which is completed when a patient enrolls in the Medicare ESRD program. Follow-up started after completing 3 months of hemodialysis therapy (baseline) and ended at the time of first endpoint, death, potential data errors, or loss to follow-up (30-day gap in outpatient dialysis or inpatient claims); which ever happened first, or six months after patient entry.
The two endpoints of interest were all-cause mortality and a composite outcome including death or hospitalization for myocardial infarction (MI), stroke or congestive heart failure (CHF), as identified by International Classification of Diseases (ICD)-9 codes on Medicare hospital claims. These outcomes are similar to those used in two recent epoetin randomized trials [10, 11] . Data on hematocrit and epoetin therapy were obtained from claims for dialysis services submitted by the dialysis facilities for payment by Medicare. Potential confounders were sociodemographics, body mass index, severity of illness and comorbidities (e.g., cerebrovascular disease, chronic obstructive pulmonary disease), amputation, inability to ambulate, receipt of parenteral iron therapy), dialysis facility characteristics, and predialysis use of ESA therapy. All variables included in this study are listed in Table 1 .
We emulated the "per protocol" analysis of a randomized clinical trial that compares the high Hct and low Hct strategies if all subjects had adhered to their baseline strategy throughout the entire follow-up. We classified eligible USRDS patients as following one or both of the following strategies: High Hct Strategy: intravenous epoetin alfa to achieve and maintain hematocrit values of 34.5-<39.0% or Low Hct Strategy: intravenous epoetin alfa to achieve and maintain hematocrit values of 30.0-<34.5%. Under both the strategies, monthly epoetin dose is changed according to the following rules: iii. If previous hematocrit is above the target range, epoetin dose is decreased ≥25% or withheld.
The administration of IV iron during the month after the patient undergoes hemodialysis in a facility not participating in the study (e.g., hospital, hospice, nursing home or home health services) and after epoetin dose was withheld, is left to the discretion of the treating physician. We could not directly evaluate the FDA recommended strategy (target Hct<33%) because only a few patients were treated under this strategy during the study years.
For each month of follow-up, if a patient's data were consistent with both strategies (for example, a patient with hematocrit <30% whose epoetin dose was increased by>10%), we created an exact copy of the patient's data for each strategy [12] . Patients assigned to a strategy were artificially censored when their treatment data ceased to be consistent with that strategy.
Because higher epoetin doses are more likely to be prescribed to patients with lower hematocrits who also might be at higher mortality and cardiovascular risk, the estimates from our model needed to be adjusted for the effect of time-dependent confounding by indication [13] . In other words, a technique is needed that addresses the issue of confounding by indication; i.e., whether higher epoetin doses correlate with higher Hct levels or more epoetin resistance and lower achieved Hct levels -a conundrum affecting nearly all observational studies using conventional statistical techniques which adjust for confounding Note: Low hematocrit (Low-Hct) strategy: treatment with epoetin alfa to target hematocrit value 30.0-<34.5 % High hematocrit (High-Hct) strategy: treatment with epoetin alfa to target hematocrit value 34.5-<39.0 % ~Data was collected in the first three months before baseline.
a Cardiovascular comorbidities include congestive heart failure, atherosclerotic heart disease, cerebrovascular disease, CVA/TIA, peripheral vascular disease, and other cardiac disease.
b Charlson Index is a tool to assess comorbidity and predict survival that has been adapted for use in ESRD patients.
c Includes amputation, inability to ambulate, and inability to transfer.
factors at baseline only. As previously described, [14] we used inverse probability (IP) weighting to adjust for time-dependent confounding by measured time varying covariates including hematocrit, iron treatment, and hospitalization. Specifically, in contrast to more traditional statistical techniques that cannot When the outcome of interest was death only, we also adjusted the model for hospitalization due to CHF, MI, and stroke. Each patient received a time-varying weight inversely proportional to the estimated probability of having his/her own observed epoetin dose history. Specifically, we used stabilized IP weights to adjust for selection bias due to artificial censoring discussed above [21] . We truncated the weights to a maximum value of 20 (with a mean of 1.1 and standard error of 2.5) for statistical efficiency. Finally, we estimated the survival curves under each treatment strategy by using the predicted values of weighted outcome models that included an indicator for treatment strategy, baseline covariates, month of follow-up (cubic splines), and product ("interaction") terms between the treatment strategy indicator and the month variables. Point-wise 95% confidence intervals for all parameter estimates were calculated via percentile-based non-parametric bootstrap based on 300 full samples. Separate analyses were conducted after including patients who did not reach hematocrit of 30% at baseline (non responders). All analyses were conducted with Statistical Analysis System (SAS) 9.1 (SAS Institute, Cary, NC).
Results
Of 112,449 elderly dialysis patients who initiated epoetin treatment between January 2006 and December 2008, 29,232 patients met the study eligibility criteria. Of 17,291 (59.2%) who were diabetic, 3,637 were classified in the Low Hct strategy only, 5,390 in the High Hct strategy only, and 8,264 in both. There were no important differences between Low Hct and High Hct patients in patient characteristics or dialysis facilities in which they received care. During the 6-month follow-up, there were 467 deaths (643 composite events) under the Low Hct strategy and 766 deaths (1,048 composite events) under the High Hct strategy. We estimated no difference (0.0%) in absolute 6-month survival or composite endpoint between the High Hct and Low Hct strategies (Figure 1 ). The hazard ratios (HRs) (95% CI) for the High Hct vs. Low Hct strategy were 1.07 (0.83, 1.38) for death and 1.00 (0.81, 1.24) for the composite event ( Figure 1) . Patient results are provided in a supplemental electronic appendix.
Conclusions
Using observational data, we emulated a randomized trial of elderly dialysis patients with diabetes assigned to either a high range hematocrit target (34.5-<39%) or a low range (30-<34.5%) treatment target. We found no differences in the rates of mortality or the cardiovascular composite between these two clinical strategies.
Our study addressed questions left unanswered by TREAT, a recent randomized trial of diabetic CKD predialysis patients [7] This trial found no cardiovascular or renal benefits and an increased stroke risk for those assigned to a target hematocrit level of 39% compared with those assigned to rescue treatment for hematocrit levels<27%. However, TREAT enrolled predialysis diabetic patients and therefore the generalizability of their findings to the dialysis populations is uncertain. Our study included ESRD dialysis patients with diabetes. Second, the 4,038 person TREAT trial was not designed to ascertain the optimal hematocrit range and therefore this question remains unanswered. Last, the TREAT investigators themselves suggest that it is possible that other dosing strategies could be developed to mitigate the risks found in their study that targeted a hematocrit of 39%, while conserving the modest benefits of treatment.
In this research, we used the largest observational data available for ESRD research and appropriate analytic methods to handle time-varying treatments and confounders from complex longitudinal administrative data. There are, however, important study limitations. First, the validity of our estimates depends on the assumption that all confounding factors were correctly measured and included in the model [22] . Since epoetin treatment was not randomized, residual confounding could still remain. Second, our analytic method relies on artificial censoring of patients who deviate from their baseline strategy and thus constrained the analysis to a shorter follow up than TREAT. Finally, study results suggesting that a higher hematocrit target does not confer any additional benefits among elderly hemodialysis patients with diabetes is limited to the following population: patients without a history of cancer, previous renal transplant, or severe anemia (Hct<24%) at dialysis initiation, who were not hospitalized for stroke, congestive heart failure or myocardial infarction in the first 3 months of dialysis, and who were deemed responders to epoetin therapy (achieving a hematocrit of 30% at baseline) (Supplemental Figure 1) .
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